Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has The Blood Screening Market Growth Evolved From 2024 To 2025, And What’s Ahead?
The scale of the blood screening market has experienced significant enlargement in the past few years. It is projected to escalate from $3.15 billion in 2024 to $3.44 billion in 2025, with a compound annual growth rate (CAGR) of 9.4%. The notable growth during the historical phase is due to escalating demands for blood transfusions, an increased incidence of communicable diseases, governmental regulations and standards, a rise in blood donations and collection, and worldwide health anxieties and pandemics.
The size of the blood screening market is anticipated to experience significant expansion in the forthcoming years. Predictions state that it will amplify to $5.33 billion by the year 2029, boasting a compound annual growth rate (CAGR) of 11.5%. The predicted growth during the forecast period can be accredited to advancements in healthcare infrastructure, initiatives promoting public health awareness, advancements in the diagnosis of infectious diseases, worldwide health apprehensions, and readiness for pandemics. The forecast period will witness major trends such as an increase in infectious diseases, enhancement in automation and efficiency, a surge in the requirements for blood transfusion, focus on the safety during transfusion, and research into pathogen detection.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9047&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Blood Screening Market?
The surge in infectious diseases is anticipated to fuel the expansion of the blood screening market. A common procedure involves examining blood for illness symptoms by identifying a specific antibody produced to combat the infectious pathogen. This is a crucial tool for medical professionals in managing infectious diseases, and preventing infection from spreading among patients and from person to person. The National Center for Biotechnology Information, an American government agency, reported in June 2022 that the occurrence of infectious diseases in outpatient care had nearly tripled over two decades, going from 8 to 26 per 1,000. Therefore, the rise in infectious diseases is catalyzing the growth of the blood screening market.
Which Key Market Segments Comprise the Blood Screening Market and Drive Its Revenue Growth?
The blood screeningmarket covered in this report is segmented –
1) By Product: Reagents And Kits; Instruments; Software And Services
2) By Technology: Nucleic Acid Testing; Enzyme-Linked Immunosorbent Assay (ELISA); Rapid Tests; Western Blot Assays; Next-Generation Sequencing (NGS)
3) By End User: Blood Banks; Diagnostic Centers And Pathology Labs; Hospitals; Clinics; Ambulatory Surgical Centers (ASCs)
Subsegments:
1) By Reagents And Kits: Diagnostic Reagents; Testing Kits
2) By Instruments: Automated Analyzers; Manual Testing Equipment
3) By Software And Services: Laboratory Information Management Systems (LIMS); Data Analysis Software; Support And Consulting Services
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=9047&type=smp
Which Areas Are Leading Regions in the Blood Screening Market Expansion Across the Globe?
North America was the largest region in the blood screening market in 2024. The regions covered in the blood screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Are the Strategic Trends Steering theBlood Screening Market Direction?
Prominent firms that are active within the blood screening sector are driving the creation of technologies such as liquid biopsy. This method aims to improve early cancer identification, optimize the supervision of treatments, and facilitate personalized medicine strategies. Liquid biopsy is a lightly intrusive examination that reviews blood or other body fluids to identify cancer cells or genetic substances from tumors. For example, Guardant Health, Inc., a biotechnology company based in the US, introduced Shield blood-based screening tests in November 2023. The test known as Shield inspects cell-free DNA (cfDNA) located in the bloodstream, which could signify the existence of precancerous growths or colorectal tumors. It specifically searches for changes in DNA fragments that enter the bloodstream from cancer cells.
View the full report here:
https://www.thebusinessresearchcompany.com/report/blood-screening-global-market-report
How Is the Blood Screening Market Conceptually Defined?
Blood screening refers to a method of screening blood, plasma, or blood components for transfusion or use in blood products. It is used to screen for antibodies or tumor markers, to seek for disease-causing substances or symptoms, or to evaluate treatment effectiveness.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9047
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model